secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2026-08-06T20:40:40+00:00
Accession:  0001213900-26-086190
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada reports Q2 net loss $12.9M; cash $217.7M; NDV-01 IND on track for YE26
------------------------------------------------------------------------------

- Net loss of $12.9M ($0.11/share) vs $9.9M loss in Q2 2025; R&D expense rose to $8.4M from $2.8M.
- Cash, equivalents, and short-term investments of $217.7M as of June 30, 2026, expected to fund operations through 2029.
- NDV-01 IND filing expected by year-end 2026; Phase 3 RESCUE program initiation upon IND clearance.
- Sepranolone IND filing expected by year-end 2026; Phase 2 proof-of-concept in Prader-Willi Syndrome upon clearance.
- Appointed Bipin Dalmia as Chief Business Officer; added to Russell 2000 and 3000 indexes in June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390026086190/0001213900-26-086190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390026086190/ea0300993-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-086190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer